Search clinical trials for: 89Zr DFO-MSTP2109A

Total 772 results

Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Completed

Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer

Prostate Cancer

United States
Telix International Pty Ltd

Completed

89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study (89ZR-TLX250)

Clear Cell Renal Cell Carcinoma

United Kingdom, United States, Australia, Turkey, Netherlands, Belgium, Canada, France
Telix International Pty Ltd

Completed

Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC (ZIRDAC-JP)

Carcinoma, Renal Cell | Clear Cell Renal Cell Carcinoma

Japan
Telix International Pty Ltd
Grand Pharmaceutical (China) Co., Ltd.

Completed

Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma (ZIRDOSE-CP)

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Cancer | Suspected Recurrent Renal Clear Cell Carcinoma

China
Telix International Pty Ltd

Recruiting

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Soft Tissue Sarcoma | Cervical Cancer | Nasopharyngeal Carcinoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Glioblastoma Multiforme | Non Small Cell Lung Cancer | Cholangiocarcinoma | Epithelial Ovarian Cancer | Head and Neck Squamous Cell Carcinoma and other conditions

United States
Telix International Pty Ltd

Available

89Zr-DFO-girentuximab Expanded Access Program (EAP)

Clear Cell Renal Cell Carcinoma

United States
Université de Sherbrooke
Eli Lilly and Company; Chorus Wellness Inc.; AL-S Pharma AG

Recruiting

Safety and Dosimetry of a New Radiotracer to Detect Misfolded SOD1 Associated With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

Canada
Robert Flavell, MD, PhD

Suspended

Zr-89 Cimzia PET Imaging Rheumatoid Arthritis

Rheumatoid Arthritis

United States
University of Saskatchewan

Recruiting

Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)

Colorectal Cancer | Lung Cancer

Canada
Monopar Therapeutics

Recruiting

Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Lung Cancer | Bladder Cancer | Urothelial Carcinoma | Triple-negative Breast Cancer | Solid Tumor, Adult

Australia
Memorial Sloan Kettering Cancer Center
BioNTech SE

Recruiting

Study of a New Technique for Imaging Pancreatic Cancer

Pancreatic Cancer | Tumors That Express CA19-9

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)

DLBCL | Large B-cell Lymphoma

United States
BioNTech Research & Development, Inc.
SciQuus Oncology

Terminated

Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1

Pancreatic Carcinoma | Tumors That Express CA19-9

United States
Aplagon Oy
TRACER Europe BV

Recruiting

Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography) (CHASE)

Peripheral Arterial Occlusive Disease | Critical Limb Ischemia

Netherlands
Memorial Sloan Kettering Cancer Center

Withdrawn

A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma

Multiple Myeloma
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors

Pituitary Adenoma | Brain Cancer

United States
ImaginAb, Inc.

Completed

Comparison of PET With [89Zr]-Df-IAb2M and [111In]-Capromab Pendetide in the Detection of Prostate Cancer Pre-Prostatectomy

Prostate Cancer

United States
ImaginAb, Inc.

Completed

Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer (IAB2M)

Metastatic Prostate Cancer

United States
ImaginAb, Inc.

Withdrawn

A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer

Prostate Cancer

United States
University Medical Center Groningen
Regeneron Pharmaceuticals

Active, not recruiting

LAG3 PET Imaging in Advanced Solid Tumors

Metastatic Solid Tumor

Netherlands
ImaginAb, Inc.

Recruiting

Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies (iPREDICT)

Melanoma | Renal Cell Carcinoma | Non Small Cell Lung Cancer | Merkel Cell Carcinoma, Unspecified

United States, Australia, Belgium, Netherlands, Switzerland, United Kingdom
Amsterdam UMC, location VUmc
AstraZeneca

Recruiting

89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study (HER Image)

Breast Cancer | Gastric Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric Cancer

Netherlands
Memorial Sloan Kettering Cancer Center

Completed

PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer

Esophagogastric Cancer

United States
Radboud University Medical Center
ImaginAb, Inc.

Recruiting

CD8+ T-cell PET/CT Imaging in COVID-19 Patients (Tangelo)

PET Imaging | Lymphopenia Due to COVID-19 | T-cell

Netherlands
Telix International Pty Ltd
Merck KGaA, Darmstadt, Germany

Recruiting

Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors

Advanced Solid Tumor | Solid Tumor, Adult | Advanced Renal Cell Carcinoma

Australia
Memorial Sloan Kettering Cancer Center
Weill Medical College of Cornell University; Broad Institute

Completed

Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Early Cancer Detection in People at High Risk of Developing Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic Cyst

United States
Memorial Sloan Kettering Cancer Center

Recruiting

PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

Small Cell Lung Carcinoma | Small Cell Lung Cancer

United States
Azienda Ospedaliera V. Cervello

Completed

Efficacy Study of the Use of Sequential DFP-DFO Versus DFP (SEQDFPDFO)

Beta-Thalassemia | Thalassemia Major

Italy
ImaginAb, Inc.
University of Hull

Recruiting

CD8 Minibody Repeatability Study (PRETZCEL)

Melanoma | Renal Cell Carcinoma

United Kingdom
Robert Flavell, MD, PhD
National Cancer Institute (NCI)

Recruiting

Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

Multiple Myeloma | Plasma Cell Myeloma

United States
James Brugarolas

Recruiting

89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Affiliated Hospital of Jiangnan University

Recruiting

89Zr-labeled NY008 PET Imaging in Patients

Multiple Myeloma

China
Wuxi No. 4 People's Hospital

Not yet recruiting

Safety Study of 89Zr-Anti-CLDN18.2 mAbs PET Imaging in Patients With CLDN18.2 Positive Solid Tumors

Solid Tumor, Adult

China
South Metropolitan Health Service
Telix Pharmaceuticals (Innovations) Pty Limited

Completed

Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients (ZiPUP)

Urothelial Carcinoma

Australia
Wuxi No. 4 People's Hospital

Unknown

89Zr-labeled KN035 PET Imaging in Patients With PD-L1 Positive Solid Tumors

Solid Tumor, Adult

China
Radboud University Medical Center
ABX CRO; Telix International Pty Ltd

Completed

89Zr-girentuximab ) Dosimetry in CCRC Study - ZIR-DOSE

Clear Cell Renal Carcinoma

Netherlands
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)

Lymphoma | Metastatic Malignant Solid Neoplasm

United States
Ain Shams University

Unknown

Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload

Sickle Cell Disease | Beta-thalassemia Major | Iron Hemosiderosis

Egypt
University of Alabama at Birmingham

Recruiting

Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness

Breast Cancer

United States
University Medical Center Groningen

Completed

Pembrolizumab-PET Imaging

Melanoma | Non-small Cell Lung Cancer

Netherlands
Wuxi No. 4 People's Hospital

Not yet recruiting

Safety Study of 89Zr-NY001 PET Imaging in Patients

Solid Tumor, Adult

China
The First Affiliated Hospital of Soochow University
MITRO Biotech Co., Ltd.

Unknown

89Zr-KN035 PET Imaging in Patients With Advanced Solid Tumors

Solid Tumor, Adult

China
Affiliated Hospital of Jiangnan University

Recruiting

89Zr-labeled NY009 PET Imaging in Patients

Cancer

China
Sinotau Pharmaceutical Group

Not yet recruiting

Clinical Study on PET Imaging, Distribution and PK of 89Zr-CD147 in Patients With Solid Tumors

Solid Tumor
Boehringer Ingelheim

Recruiting

A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

Melanoma | Non-small Cell Lung Cancer (NSCLC) | Carcinoma, Squamous Cell of Head and Neck (HNSCC)

Netherlands
University Medical Center Groningen
Genentech, Inc.; Amsterdam UMC, location VUmc

Completed

89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients (MMOT)

Digestive System Diseases | Ovarian Diseases | Adnexal Diseases | Digestive System Neoplasms | Pancreatic Neoplasms | Ovarian Neoplasms | Pancreatic Diseases

Netherlands
Huashan Hospital

Unknown

The Research on 89Zr-ABT806 PET Imaging in High Grade Glioma

Glioma

China
Institut Cancerologie de l'Ouest
ATONCO

Completed

Assessment of safEty, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled giRenTuximab (89Zr-Girentuximab) in patIents With Non-musclE-iNvasive Bladder CancEr (NMIBC) (PERTINENCE)

Bladder Cancer

France
University Medical Center Groningen

Completed

89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition (AUY922)

Breast Cancer

Netherlands

Search clinical trials for: 89Zr DFO-MSTP2109A

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations